4.3 Review

Early epigenetic cancer decisions

期刊

BIOLOGICAL CHEMISTRY
卷 395, 期 11, 页码 1315-1320

出版社

WALTER DE GRUYTER GMBH
DOI: 10.1515/hsz-2014-0185

关键词

cancer; cancer stem cell; cancer therapy; oncogenes; stem cells; tumoural reprogramming

资金

  1. FEDER
  2. MICINN [SAF2012-32810]
  3. NIH [R01 CA109335-04A1]
  4. ARIMMORA project (European Union Seventh Framework Program) [FP7-ENV-2011]
  5. Junta de Castilla y Leon [BIO/SA06/13]
  6. Deutsche Jose Carreras Leukamie-Stiftung (DJCLS project) [13/26]
  7. European Union FEDER program
  8. European Union [315902]

向作者/读者索取更多资源

A cancer dogma states that inactivation of oncogene(s) can cause cancer remission, implying that oncogenes are the Achilles' heel of cancers. This current model of cancer has kept oncogenes firmly in focus as therapeutic targets and is in agreement with the fact that in human cancers all cancerous cells, with independence of the cellular heterogeneity existing within the tumour, carry the same oncogenic genetic lesions. However, recent studies of the interactions between an oncogene and its target cell have shown that oncogenes contribute to cancer development via developmental reprogramming of the epigenome within the target cell. These results provide the first evidence that carcinogenesis can be initiated by epigenetic stem cell reprogramming, and uncover a new role for oncogenes in the origin of cancer. Here we analyse these evidences and discuss how this vision offers new avenues for developing novel anti-cancer interventions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据